Q-omics provides the consensus-scored SCAF8 profile across patient tissues and cancer cell-line models. SCAF8 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SCAF8 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SCAF8 protein abundance shows 23,059 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where SCAF8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCAF8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCAF8 survival associations across molecular data types. SCAF8 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCAF8 RNA expression–survival associations across cancer types. High SCAF8 expression shows unfavorable associations in LIHC, MESO and OV, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SCAF8 RNA expression.
This table summarizes SCAF8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SCAF8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCAF8 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and STAD. The THCA box plot shows higher SCAF8 RNA expression in normal versus tumor tissue (log2 FC = −0.904, t-test p < 0.001).
This table shows molecular features associated with SCAF8 in patient tissues and cancer cell lines. In patient samples, SCAF8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCAF8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
